GVGalina Velikova

Galina Velikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Galina Velikova has a total of 971 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review

    by Tamara Jones, Andreia Ferreira Moura, Waleed Alrjoub, Cecilie Delphin Amdal, Johannes M. Giesinger, Alexandra Gilbert, Mogens Groenvold, Hayat Hamzeh, Zsuzsanna Iyizoba, Michael Koller, et al.

  • Open Access

    Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)

    by Christopher Bedding, Kate Absolom, Katarzyna Pogoda, Akihiko Shimomura, Hiroto Ishiki, Juan Ignacio Arraras, Julien Peron, Monica Pinto, Nora Nevries, Omar Shamieh, et al.

  • Open Access

    International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

    by Louis Fox, Marieke van Leeuwen, Jennifer M. Jones, Amal Al-Omari, Haneen Abaza, Muna Al-Khaifi, Martin Eichler, Sue Hartup, Galina Velikova, Nanna Friðriksdóttir, et al.


  • Open Access

    Online symptom monitoring for lung cancer patients receiving systemic therapy: a feasibility implementation project

    by Sarah Reddy, Andrea Gibson, Rosemary Peacock, Christopher Bedding, Cheryl Armstrong, Robert Carter, Katy Clarke, Rosie McDonald, Majid Riaz, Galina Velikova

    Modern systemic anti-cancer therapies have resulted in an improved prognosis for lung cancer patients. However, their complex toxicities require close monitoring. An existing e-Health platform called eRAPID (Electronic patient self-Reporting of Adverse events: Patient Information and aDvice), enables patients to report symptoms and receive automatic severity-dependent advice to self-manage or contact the hospital. Symptom data is available in real-time for clinicians in the patients' electronic patient record (EPR). The feasibility study aimed to implement eRAPID for symptom/toxicity monitoring of lung cancer patients during and after systemic therapy. Primary outcomes were recruitment and consent rates, attrition rates and adherence to symptom reporting. Secondary outcomes were: (I) type, frequency, and severity of self-reported symptoms; (II) activated clinical algorithms for patient advice; and (III) patient and staff acceptance and views. Consecutive patients starting systemic therapy were recruited and followed up for 12-months. Participants joined Cohort 1 (online access, reporting weekly from home) or Cohort 2 (no online access, completing before appointments every 4-6 weeks with assistance). Patients completed symptom reports, designed with the lung clinicians, plus 3 monthly quality-of-life questionnaires (EuroQol-5 dimensions). Descriptive analysis was employed for the quantitative outcomes. Semi-structured interviews and online feedback gathered views from a subset of patients and clinicians, using thematic framework analysis. Study project registration number: NCT04324437. Between August 2020 and July 2022, eighty-five patients were eligible, 43 (50.6%) consented, 33 Cohort 1, 10 Cohort 2. The attrition rate was 65.1% (28/43) primarily due to disease progression. For all patients, a total of 841 symptom reports were generated. For Cohort 1, the mean weekly adherence for symptom reporting was 68.9% (range, 50-70%). The most reported symptoms were fatigue (77%), physical limitations (76%), pain (60%) and shortness of breath (59%), but they were mainly mild. The clinical algorithm generated 56 notifications to the clinical team for severe symptoms (6.7%, 56/841), with physical limitations and rash most common. Three-monthly adherence to quality-of-life questionnaires was 60-90%. Patient and staff feedback (n=14 and n=9) revealed reassurance and confidence from patients in self-managing side-effects. Although clinicians did not always discuss the reported symptoms, patients felt more connected to their healthcare team. Clinicians valued eRAPID for tracking symptoms, planning consultations, making timely clinical decisions and improving patient relations. The eRAPID approach was accepted by half of the patients who were eligible to take part. There was good adherence over time, and willingness to complete 3-monthly quality of life measures. Clinicians and patients supported the intervention for routine practice but required further investment and support from the hospital to make the symptom monitoring sustainable.

  • Open Access

    Health-related quality of life domains relevant to people in Europe undergoing cancer treatment: a systematic review of qualitative research

    by Catalina Lizano-Barrantes, Clara Amat-Fernandez, Olatz Garin, Yolanda Pardo, Óscar Périz-Colón, Pablo Notti Saint-Jean, Leslye Rojas-Concha, Melissa Thong, Giovanni Apolone, Cinzia Brunelli, et al.

    To identify and synthesize evidence from European qualitative studies on cancer-related quality of life outcomes, needs, experiences, preferences, and concerns of people undergoing cancer treatment in the last decade. Systematic review ( https://www.crd.york.ac.uk/PROSPERO , CRD42024575065) of European studies using qualitative methodology, assessing constructs related to HRQoL, and involving adults receiving cancer treatment. The search was performed in PubMed and Scopus from January 2013 to July 2024. Titles, abstracts, and full texts screening, data extraction and risk of bias assessment were conducted independently by two researchers. The main outcomes were the themes reported in each study. The thematic analysis was performed by organizing the themes of the studies into categories. Out of 18,256 articles initially identified, 36 met the inclusion criteria: 21 with generic and 15 with specific objectives. Five categories encompassing 110 themes were identified from the generic studies: Psychological Function (n = 41), Clinical Management (n = 26), Symptoms and Physical Function (n = 18), Social Function (n = 16), and Life Disruption (n = 9). Eleven studies with specific objectives focused on clinical management with all their themes fitting within the categories identified in the generic studies. Results showed the predominance of psychological function and clinical management themes. Symptoms and physical function, social function, and life disruption maintained their importance within the classical HRQoL framework. The emergence of clinical management is consistent with the growing patient-centered care approach, suggesting the need to integrate this content into the evaluation of patients undergoing cancer treatment. most European countries were not represented, and publication bias could hide traditional domains.

  • Open Access

    The development of the European Toolkit for the self-assessment of quality of life across the cancer care continuum (EUonQoL-Kit)

    by Emma Nicklin, Christopher Bedding, Sara Alfieri, Giovanni Apolone, Volker Arndt, Nanne Bos, Anne Bredart, Cinzia Brunelli, Luana Caselli, Gennaro Ciliberto, et al.


  • Open Access

    Clinicians’ Experiences of Implementing Clinical Frailty Scale Assessments in Lung Oncology Clinics: A Qualitative Interview Study

    by Jessica Pearce, Hayat Hamzeh, Mary Denholm, Alastair Greystoke, Fabio Gomes, Andrew Clegg, Galina Velikova, Suzanne H. Richards, Alexandra Gilbert

    Background/Objectives: Simple frailty assessments, such as the clinical frailty scale (CFS), are prognostic for worse outcomes in older adults with cancer and could support treatment decision-making. This interview study aims to explore clinicians’ experiences of using simple frailty assessments in oncology, including the impacts on patient care and barriers and facilitators to successful implementation. Methods: Semi-structured individual interviews were conducted with clinicians at three UK sites that had implemented CFS screening in lung cancer clinics as part of a national pilot, to explore how frailty assessments are applied and are impacting care. Purposive sampling targeted a range of professionals involved in assessing frailty and making treatment decisions. Recordings were transcribed verbatim and analysed thematically. Results: Ten clinicians participated, and four main themes were identified. ‘Assessing fitness and frailty’ explores the central role of performance status (PS), as well as its limitations, and what frailty assessments add. ‘Scoring and interpreting CFS’ describes the ease and relative yield of CFS use, particularly for patients with ‘borderline’ PS scores (e.g., PS 1–2 or 2–3), and the importance of contextual interpretation. ‘Role of frailty and impacts of assessment’ highlights how frailty assessments can enhance patient-centered care and support, and clinical and shared decision-making, with potential for streamlined care and system-level benefits. ‘Barriers and facilitators to implementation’ are described, including time, culture, guidance, and training, with recommendations provided. Conclusions: Assessing frailty has wide-ranging potential benefits for patients, oncology teams, and the wider system, but barriers must be overcome. Specific recommendations are provided to support the routine implementation of frailty assessments, which is a key step towards the benefits of frailty-informed care being realised at scale.

  • Top Cited Papers
    Open Access

    Needs and health-related quality of life domains relevant to people in Europe with advanced cancer in need of palliative care: a systematic review of qualitative research

    by Catalina Lizano-Barrantes, Clara Amat-Fernandez, Olatz Garin, Ricardo Luer-Aguila, Yolanda Pardo, Leslye Rojas-Concha, Melissa S Y Thong, Giovanni Apolone, Cinzia Brunelli, Augusto Caraceni, et al.

    Purpose: There is a need for a comprehensive summary of qualitative research on the health-related quality of life (HRQoL) of people with advanced cancer requiring palliative care. We aim to systematically review qualitative studies on outcomes, needs, experiences, preferences, concerns and HRQoL of people in Europe with advanced cancer requiring palliative care over the last decade. Methods: Protocol registered ( www.crd.york.ac.uk/PROSPERO , CRD42024575065). The search was conducted in PubMed and Scopus, from 2013 onward. Inclusion criteria: qualitative studies addressing constructs related to the HRQoL of adults with cancer requiring palliative care in Europe. Abstracts and full texts were reviewed, data extracted, and risk of bias assessed independently by two researchers. A thematic analysis stratified by study objective was performed, grouping the emerging themes into categories (primary outcome). Results: Of 18,256 articles identified, 20 fulfilled the inclusion criteria: 10 studies with a generic objective (whole palliative process or end-of-life phase), and 10 with specific focuses. Five categories (35 themes) emerged from the studies with generic focuses: ‘Psychological Function’ ( n = 15), ‘Clinical Management’ ( n = 8), ‘Symptoms and Physical Function’ ( n = 6), ‘Social Function’ ( n = 5), and ‘End-of-life’ ( n = 1). Themes from the 7 studies focusing on treatment, services, and self-management also fitted into these categories, adding ‘Spiritual Well-being’. Conclusion: These findings emphasise the predominance of the psychological function domain in cancer patients requiring palliative care, including cancer-related anxiety and distress, coping mechanisms, control and decision-making, and fearing and expecting death. Additionally, clinical management unmet needs were identified in health care, information and communication, and end-of-life settings (home vs. hospital).


  • Open Access

    The development of the European Toolkit for the self-assessment of quality of life across the cancer care continuum (EUonQoL-Kit)

    by Emma Nicklin, Christopher Bedding, Sara Alfieri, Giovanni Apolone, Volker Arndt, Nanne Bos, Anne Bredart, Cinzia Brunelli, Luana Caselli, Gennaro Ciliberto, et al.

    PurposeThe European Oncology Quality of Life (EUonQoL) project aims to develop a questionnaire toolkit (EUonQoL-Kit) to assess the quality of life (QoL) of cancer patients and survivors across Europe.MethodsThe EUonQoL-Kit development used mixed-methods and a co-design approach. Data was collected in six countries (Denmark, France, Germany, Italy, Netherlands and UK). The target populations were patients in active treatment (A), survivors (B) and patients requiring palliative care (C). A review of existing QoL theoretical models produced an initial EUonQoL conceptual framework. Semi-structured interviews and a Delphi survey evaluated/modified the framework. Existing validated items were used to construct the toolkit, including Computer Adaptive Testing (CAT), where available. A usability study evaluated EUonQoL-Kit.v1. Data triangulation and consensus methodology guided EUonQoL-Kit.v2.ResultsThe initial conceptual framework covered four multi-dimensional domains: physical, social and overall health, and psychological wellbeing. The interviews and Delphi survey included 75 and 155 participants, respectively. The domain ‘healthcare experience’ was identified and included in the framework. EUonQoL-Kit.v1 resulted in three static questionnaires, one for each target population (n items- A=75; B=67; C=79). Following usability testing with 53 participants, EUonQoL-Kit.v2 was produced via a multi-stakeholder consensus development panel, creating a shortened version (n items- A=50; B=50; C=44). Dynamic versions of these questionnaires were developed using the EORTC CAT Core system.ConclusionsEUonQoL-Kit is a novel toolkit developed to assess QoL across the cancer continuum and inform health policy within Europe. Its psychometric properties are currently being evaluated using data collected on more than 4200 patients across 32 countries.

  • Open Access

    Electronic patient-reported adverse event monitoring in academic early-phase clinical trials: A feasibility study

    by Leanne Shearsmith, Sarah Danson, Sarah Gelcich, Andrea Gibson, Kathryn Gordon, Fiona Collinson, Julie Croft, Emma Griffiths, Zoe Rogers, Robert Carter, et al.

    Background: Adverse event monitoring is essential to monitor safety for oncology patients on early-phase clinical trials. Previous research considers that electronic patient-reported adverse events reporting is feasible and complementary to traditional clinician-led recording. An electronic patient-reported adverse event system was developed to explore the feasibility of this in early trials patients. Methods: A prospective single-arm feasibility study was undertaken at two recruiting hospitals. Participants were adult oncology patients who had recently (<1 month) started receiving a novel anticancer treatment on an academic early-phase trial and had access to the Internet. For a 12-week period, weekly reminders were sent to participants to complete an electronic patient-reported adverse event questionnaire remotely covering symptoms identified as relevant to the recruiting trials. The primary outcome was compliance (proportion of completed questionnaires/expected completions). Secondary outcomes included recruitment rates, attrition, electronic patient-reported outcome versus clinician-recorded adverse events, number of notifications, issues recorded, and patient acceptability. Results: Twenty-three participants consented (76.7% consent rate), 18 remained on study at 12 weeks (4 were withdrawn due to toxicity and 1 patient choice). Compliance with weekly electronic patient-reported adverse event was high, with a cumulative of 85.1% across the 12 weeks. Comparison with clinician-recorded adverse events showed electronic patient-reported adverse event resulted in wider coverage of adverse events: three times as many symptoms reported on electronic patient-reported adverse event (n = 174 last assessment) than recorded in the medical charts (n = 50 last record). End-of-study feedback indicated most patients reflected positively on their time on the study. Conclusions: Remote electronic patient-reported adverse event reporting by patients in early-phase trials is feasible and acceptable. The study highlights some logistical challenges that require consideration in future electronic patient-reported outcome work to ensure adverse events are fully captured and recorded. Trial registration: ClinicalTrials.gov ID: NCT03461939 (first registered: 05/03/2018)